AstraZeneca PLC (AZN)
AZN Price and Sentiment
AZN Latest news
AstraZeneca PLC (LSE:AZN) releases third quarter results on Friday with shareholders feeling good despite the company perhaps not getting the kudos it deserved for its COVID-19 vaccine efforts. Stockbroker AJ Bell noted a positive outlook for the FTSE 100 stalwart, given the recent performance of the shares despite the weight of the COVID-19 vaccine (which is sold at cost and is overall loss making).
The number of companies reporting quarterly earnings this week has swelled to more than 1,000 as more companies confirm their plans.
AstraZeneca PLC (LSE:AZN) was well bid during the afternoon session with analysts revisiting their spreadsheets after a flurry of news. Barclays Capital has moved its price target to £110 from £100 for shares in the Anglo-Swedish drugs giant.
AZN, GOLD, NARI, KOP, and TCEHY have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2021.
AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and coronavirus treatments after a shaky start during the pandemic. Related Link: AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters.
AstraZeneca's(AZN) third-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on sales numbers of AstraZeneca's COVID-19 vaccine.
(Reuters) -AstraZeneca is creating a separate division for vaccines and antibody therapies to be led by senior executive Iskra Rei?, the drugmaker said on Tuesday, as it builds focus on its COVID-19 shot and development of coronavirus treatments.
AstraZeneca: Lagging For A Reason
AstraZeneca shared positive interim results for Imfinzi plus chemotherapy in treating patients with advanced biliary tract cancer.